- Investing.com
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company’s products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Clinical Setbacks | Explore Arvinas's strategic shift following discontinued trials and workforce reduction, impacting its clinical development pipeline and financial outlook |
Vepdegestrant Potential | Delve into the promising prospects of Arvinas's lead candidate for ESR1 mutant breast cancer patients, with NDA filing expected in 2H 2025 |
Market Dynamics | Uncover the challenges Arvinas faces in the competitive oral SERD market, balancing innovation against established benchmarks and emerging rivals |
Financial Outlook | Analyst targets range from $10 to $48, reflecting varied perspectives on Arvinas's future amid extended cash runway and strategic realignment |
Metrics to compare | ARVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARVNPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.2x | −2.6x | −0.5x | |
PEG Ratio | −0.08 | 0.05 | 0.00 | |
Price/Book | 0.7x | 1.6x | 2.6x | |
Price / LTM Sales | 1.2x | 1.4x | 3.3x | |
Upside (Analyst Target) | 132.4% | 170.2% | 43.4% | |
Fair Value Upside | Unlock | 16.0% | 7.1% | Unlock |